METHOD FOR PREPARING PERITONEAL DIALYSATE

• US 20070020341A1
• Filed: 09/22/2006
• Published: 01/25/2007
• Est. Priority Date: 08/24/1998
• Status: Active Grant

• Current Assignee: Kiyoshi Kurokawa, Tokai University Educational System, Toshio Miyata
• Original Assignee: Toshio Miyata Kiyoshi Kurokawa and Tokai University Educational System
• Inventors: Miyata, Toshio
• Granted Patent: US 7,745,613 B2
• Time in Patent Office: Days
• US Class Current: 424/600
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 31/155 Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
• CPC Class Codes: A61K 31/203 Retinoic acids ; Salts thereof
• CPC Class Codes: A61K 31/4965 Non-condensed pyrazines
• CPC Class Codes: A61K 33/00 Medicinal preparations containing inorganic active ingredients
• CPC Class Codes: A61M 1/287 Dialysates therefor
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 7/08 Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock artificial tears A61P27/04

Abstract

Carbonyl compounds generated and accumulated in the peritoneal dialysate can be inactivated or eliminated by a carbonyl compound-trapping agent such as aminoguanidine. Carbonyl compounds generated during sterilization and storage of the peritoneal dialysate can be eliminated by pre-contacting with the trapping agent. Further, it is possible to eliminate carbonyl compounds transferred from the blood to the peritoneal cavity of the patient during peritoneal dialysis treatment, by adding the trapping agent to the peritoneal dialysate or by circulating the fluid through a carbonyl compound-trapping cartridge. Intraperitoneal protein modification by carbonyl compounds is inhibited by the present invention, thereby sufficiently reducing peritoneal disorders associated with peritoneal dialysis treatment.

Claims

1. An agent for improving intraperitoneal carbonyl-stress state during peritoneal dialysis, comprising a carbonyl compound-trapping agent as an active ingredient.

2. The agent of claim 1, wherein the carbonyl compound-trapping agent is immobilized on an insoluble carrier.

3. The agent of claim 1, wherein the carbonyl compound-trapping agent is to be mixed with a peritoneal dialysate.

4. The agent of any one of claims 1 to 3, wherein the carbonyl compound-trapping agent is selected from the group consisting of aminoguanidine, pyridoxamine, hydrazine, biguanide compound, SH group containing compound, and derivatives of these.

5. The agent of any one of claims 1 to 3, wherein the carbonyl compound-trapping agent is an agent inhibiting Maillard reaction

6. The agent of claim 1, wherein the carbonyl compound-trapping agent is a compound insoluble in peritoneal dialysates and capable of adsorbing carbonyl compounds.

7. A cartridge used for trapping carbonyl compounds within peritoneal dialysates, wherein the cartridge is filled with the carbonyl compound-trapping agent(s) of claim 2 and/or claim 6.

8. A method for preparing a peritoneal dialysate having a reduced carbonyl compound content, the method comprising passing the peritoneal dialysate through the cartridge of claim 7.

9. A method for preparing a peritoneal dialysate having a reduced carbonyl compound content, the method comprising:

(a) contacting the peritoneal dialysate with the carbonyl compound-trapping agent(s) of claim 2 and/or claim 6, and

(b) separating the peritoneal dialysate from the carbonyl compound-trapping agent.

10. A peritoneal dialysate comprising a carbonyl compound-trapping agent.

11. The peritoneal dialysate of claim 10, wherein the peritoneal dialysate further comprises a reducing sugar, and is placed in a container comprising a first compartment and a second compartment so that the first compartment contains the reducing sugar and the second compartment contains the carbonyl compound-trapping agent.

12. The peritoneal dialysate of claim 10, wherein the carbonyl compound-trapping agent is to be administered into the intraperitoneal cavity.